Yardena Samuels
#91,978
Most Influential Person Now
Israeli molecular biologist
Yardena Samuels's AcademicInfluence.com Rankings
Yardena Samuelsbiology Degrees
Biology
#11287
World Rank
#14672
Historical Rank
Molecular Biology
#2436
World Rank
#2474
Historical Rank
Download Badge
Biology
Yardena Samuels's Degrees
- PhD Molecular Biology Weizmann Institute of Science
- Bachelors Life Sciences Tel Aviv University
Why Is Yardena Samuels Influential?
(Suggest an Edit or Addition)According to Wikipedia, Yardena Samuels or Samuels-Lev is an Israeli molecular biologist who is the Director of the Ekard Institute for Cancer Diagnosis Research at the Weizmann Institute of Science. Her research considers the genetic mutations of melanoma.
Yardena Samuels's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers (2004) (3428)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells (2013) (979)
- Mutant PIK3CA promotes cell growth and invasion of human cancer cells. (2005) (867)
- The PIK3CA gene is mutated with high frequency in human breast cancers (2004) (686)
- Oncogenic mutations of PIK3CA in human cancers. (2004) (586)
- Colorectal cancer: Mutations in a signalling pathway (2005) (578)
- Oncogenic PI3K and its role in cancer (2006) (507)
- Exome sequencing identifies GRIN2A as frequently mutated in melanoma (2011) (493)
- The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations (2007) (442)
- Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer (2011) (438)
- iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human (2003) (373)
- Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 (2009) (358)
- Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions (2014) (342)
- Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas (2004) (341)
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. (2015) (294)
- iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 (2006) (273)
- ASPP1 and ASPP2: Common Activators of p53 Family Members (2004) (255)
- The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. (2007) (229)
- UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma (2019) (209)
- Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms (2006) (192)
- Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response (2021) (181)
- Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer (2016) (166)
- The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies (2014) (161)
- Analysis of the genome to personalize therapy for melanoma (2010) (160)
- Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma (2009) (158)
- Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. (2007) (155)
- Frequent mutations in the MITF pathway in melanoma (2009) (154)
- Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures (2018) (147)
- Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma (2013) (144)
- Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma (2011) (144)
- Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression (2013) (138)
- Protective roles of matrix metalloproteinases: From mouse models to human cancer (2009) (133)
- Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. (2008) (126)
- Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation (2010) (125)
- Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens (2016) (123)
- Identification of bacteria-derived HLA-bound peptides in melanoma (2021) (112)
- Molecular Pathways: Dysregulated Glutamatergic Signaling Pathways in Cancer (2012) (106)
- PIK3CA in cancer: The past 30 years. (2019) (105)
- Mutant PIK 3 CA promotes cell growth and invasion of human cancer cells (2005) (102)
- Assembly and activation of the Hippo signalome by FAT1 tumor suppressor (2018) (99)
- Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. (2018) (92)
- Co‐stimulation‐dependent activation of a JNK‐kinase in T lymphocytes (1998) (91)
- The genetics of melanoma: recent advances. (2013) (88)
- Harnessing synthetic lethality to predict the response to cancer treatment (2018) (86)
- Recurrent inactivating RASA2 mutations in melanoma (2015) (83)
- Oncogenic Mutations of PIK3CA in Human Cancers (2004) (72)
- Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma (2020) (72)
- 24 Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma (2018) (68)
- Shimmer: detection of genetic alterations in tumors using next-generation sequence data (2013) (63)
- Anti-tumour immunity induces aberrant peptide presentation in melanoma (2020) (57)
- Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation (2015) (55)
- IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. (2010) (52)
- Mutational and Functional Analysis Reveals ADAMTS18 Metalloproteinase as a Novel Driver in Melanoma (2010) (49)
- Melanoma models for the next generation of therapies. (2021) (49)
- Mechanisms of immune activation and regulation: lessons from melanoma (2022) (49)
- A highly recurrent RPS27 5'UTR mutation in melanoma (2014) (47)
- The functional relevance of somatic synonymous mutations in melanoma and other cancers (2015) (43)
- Delving into somatic variation in sporadic melanoma (2012) (40)
- YAP and the drug resistance highway (2015) (39)
- A growing family: Adding mutated Erbb4 as a novel cancer target (2010) (38)
- Analysis of the disintegrin‐metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma (2011) (35)
- Cross-talk between the receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells (2018) (33)
- Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma (2012) (33)
- Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation (2014) (29)
- The involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cells. (2016) (29)
- Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma (2016) (27)
- Mutational and Functional Analysis of the Tumor‐Suppressor PTPRD in Human Melanoma (2014) (26)
- Novel somatic mutations in heterotrimeric G proteins in melanoma (2010) (26)
- Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics (2021) (22)
- Somatic mutations in MAP3K5 attenuate its pro-apoptotic function in melanoma through increased binding to Thioredoxin (2013) (22)
- The Structure of a Human p 110 a / p 85 a Complex Elucidates the Effects of Oncogenic PI 3 K a Mutations (2007) (22)
- ERBB4 mutation analysis: emerging molecular target for melanoma treatment. (2014) (21)
- Parkin Somatic Mutations Link Melanoma and Parkinson's Disease. (2016) (20)
- The Structure of a Human p110a/p85a Complex Elucidates the Effects of Oncogenic PI3Ka Mutations (2007) (18)
- A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma (2019) (17)
- Mutational Signatures of De-Differentiation in Functional Non-Coding Regions of Melanoma Genomes (2012) (17)
- RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2018) (16)
- Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications (2017) (16)
- Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. (2018) (14)
- Cancer research in the era of immunogenomics (2018) (14)
- PhISCS-BnB: A Fast Branch and Bound Algorithm for the Perfect Tumor Phylogeny Reconstruction Problem (2020) (14)
- Erratum: Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma (Cancer Cell (2018) 33(2) (322–336.e8) (S1535610818300023) (10.1016/j.ccell.2018.01.002)) (2018) (13)
- Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells (2017) (12)
- Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation (2005) (11)
- Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors (2022) (10)
- Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. (2021) (9)
- Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally (2022) (8)
- CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma (2018) (7)
- Recurrent inactivating RASA 2 mutations in melanoma (6)
- Lack of inherited mutations of PTPRD in familial melanoma and melanoma‐astrocytoma syndrome (2009) (6)
- Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4. (2018) (6)
- RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma (2018) (4)
- Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2019) (3)
- Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities (2019) (3)
- Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry. (2018) (3)
- TYRO3‐mediated regulation of MITF: a novel target in melanoma? (2010) (3)
- Measuring the cognitive load of learning to program Measuring the Cognitive Load of Learning to Program: A Replication Study P R E P R I N T (2020) (3)
- Analysis of Enzymatic Activity of Matrix Metalloproteinase (MMP) by Collagen Zymography in Melanoma. (2018) (3)
- The proteasome regulator PSME4 drives immune evasion and abrogates anti-tumor immunity in NSCLC (2021) (2)
- MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters (2020) (2)
- IDH 1 mutation identified in human melanoma (2011) (2)
- Mutated MITF-E 87 R in Melanoma Enhances Tumor Progression via S 100 A 4 (2018) (1)
- Large-Scale Immuno-Peptidome Analysis Reveals Recurrent Post-Translational Splicing of Cancer and Immune-Associated Genes. (2023) (1)
- Inhibiting phosphoinositide 3-kinases (2005) (1)
- Abstract 3114: Mutational inactivation of STAG2 causes aneuploidy in human cancer (2012) (1)
- Genetic analysis of LOH of chromosome 1p, 19q and PIK3CA mutations in oligodendrogliomas (2005) (1)
- Erratum: The PIK3CA gene is mutated with high frequency in human breast cancers (Cancer Biology and Therapy (2004) 3 (772-775)) (2005) (1)
- Genetic and Functional Analysis of GRIN2A in Tumor Samples. (2017) (1)
- Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma (2012) (1)
- Abstract 1125: Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancers (2015) (1)
- Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma (2019) (1)
- The impact of the cancer genome project and high-throughput analyses on personalised oncology: today and tomorrow (2012) (1)
- alloproteinase as a Novel Driver in Melanoma (2010) (1)
- Mutational and Functional Analysis Reveals ADAMTS 18 Metalloproteinase as a Novel Oncogene in Melanoma (2011) (0)
- Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma (2018) (0)
- Assembly and activation of the Hippo signalome by FAT1 tumor suppressor (2018) (0)
- Abstract IA07: UVB-induced tumor heterogeneity directs immune response in melanoma (2020) (0)
- Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells (2019) (0)
- Abstract LB-065: Mutational and functional analysis of the tumor suppressor PTPRD in human melanoma (2015) (0)
- RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2018) (0)
- Towards Deciphering the Genetic Landscape in Melanoma (2012) (0)
- Huang Mutations α Effects of Oncogenic PI 3 K Complex Elucidates the α / p 85 α The Structure of a Human p 110 (2013) (0)
- Abstract 4860: Exon capture analysis of G-protein coupled receptors reveals activating mutations inGRM3in melanoma (2012) (0)
- Abstract LB-48: Somatic mutation of the NMDAR subunit GRIN2A in malignant melanoma results in loss of tumor suppressor activity. (2013) (0)
- Abstract 4970: Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma (2011) (0)
- Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells (2017) (0)
- Combination therapy for the treatment of cancer (2017) (0)
- Abstract LB-031: Deciphering distinct roles of RASA2 in melanomagenesis (2017) (0)
- Analysis of Circulating DNA Serial Assessment of Human Tumor Burdens in Mice by the (2007) (0)
- Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells (2019) (0)
- 672 Identification of microbial-derived HLA-bound peptides in melanoma (2020) (0)
- Extreme Vulnerability of ID H 1 Mutant Cancers to NAD + Depletion Graphical Abstract Highlights (0)
- Harnessing synthetic lethality to predict the response to cancer treatment (2018) (0)
- Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma (2020) (0)
- Abstract 100: Somatic mutations in Pyk2 in melanoma alter protein activity, interactions and localization (2012) (0)
- Molecular Cancer esearch cer Genes and Genomics ational and Functional Analysis Reveals ADAMTS 18 R alloproteinase as a Novel Driver in Melanoma (2010) (0)
- Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells (2019) (0)
- Abstract 2221: Analysis of the protein tryosine kinome in melanoma revealed recurrent mutations inERBB4 (2010) (0)
- 2 Links Between the PI 3 K Pathway and Cancer (2011) (0)
- Predicting the Response to Treatment Using Gene Mutation Profiling in Metastatic Melanoma Patients Principal Investigator / Institute (2008) (0)
- PIK3CA gene mutations in human cancers (2005) (0)
- NRas activity is regulated by dynamic interactions with nanoscale signaling clusters at the plasma membrane (2022) (0)
- Abstract A188: Harnessing synthetic lethality to predict the response to cancer treatments (2018) (0)
This paper list is powered by the following services:
Other Resources About Yardena Samuels
What Schools Are Affiliated With Yardena Samuels?
Yardena Samuels is affiliated with the following schools:
